Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Kaitlin Benedict, Jeremy A.W. Gold, Mitsuru Toda, George R. Thompson, Nathan P. Wiederhold, Dallas J. Smith

Producción científica: Articlerevisión exhaustiva

4 Citas (Scopus)

Resumen

Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

Idioma originalEnglish (US)
Número de artículoofad389
PublicaciónOpen Forum Infectious Diseases
Volumen10
N.º8
DOI
EstadoPublished - ago 1 2023

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Huella

Profundice en los temas de investigación de 'Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021'. En conjunto forman una huella única.

Citar esto